Perioperative tislelizumab plus chemotherapy for locally advanced resectable thoracic oesophageal squamous cell carcinoma trail: A prospective single-arm, phase II study (PILOT trial) DOI Creative Commons
Chengzhi Ding,

Yijun Guo,

Ya-Ning Zhou

et al.

Research Square (Research Square), Journal Year: 2023, Volume and Issue: unknown

Published: Oct. 31, 2023

Abstract Background The promising therapeutic outcomes of neoadjuvant immunotherapy combined with chemotherapy in the treatment locally advanced esophageal squamous cell carcinoma (ESCC) have been confirmed by several phase Ⅱ clinical trials and widely used work. Theoretically, postoperative adjuvant may further improve effect, but there is still lack evidence. aim this study was to analyze safety efficacy perioperative (tislelizumab) for resectable thoracic ESCC (PILOT trial). Methods Seventy-three eligible patients pathologically at T1b-3N1-3M0 or T3N0M0 staging will be allocated receive (tislelizumab 200mg d1, q3w × 2 cycles) plus (nad-paclitaxel 260 mg/m d1 + carboplatin AUC = 5 treatment. Patients pathologic complete response (pCR) after esophagectomy received tislelizumab (200 mg every 3 weeks up one year), non-pCR were assigned two cycles then maintenance 15 cycles). primary endpoint 2-year disease-free survival (DFS) patients. secondary endpoints include pCR rate, major pathological DFS patients, R0 resection adverse events, overall survival. Discussion This protocol has reviewed approved Ethics Committee Shanghai Chest Hospital (IS23059). first prospective trial investigate ESCC. We hypothesize that could a strategy which can provide better Trial registration ClinicalTrial.gov: NCT0605633

Language: Английский

Microglia in retinal angiogenesis and diabetic retinopathy DOI Creative Commons
Aiyan Hu, Mirko H. H. Schmidt,

Nora Heinig

et al.

Angiogenesis, Journal Year: 2024, Volume and Issue: 27(3), P. 311 - 331

Published: April 2, 2024

Abstract Diabetic retinopathy has a high probability of causing visual impairment or blindness throughout the disease progression and is characterized by growth new blood vessels in retina at an advanced, proliferative stage. Microglia are resident immune population central nervous system, known to play crucial role regulating retinal angiogenesis both physiological pathological conditions, including diabetic retinopathy. Physiologically, they located close essential for forming (neovascularization). In retinopathy, microglia become widely activated, showing distinct polarization phenotype that leads their accumulation around neovascular tufts. These activated induce pathogenic through secretion various angiogenic factors status endothelial cells. Interestingly, some subtypes simultaneously promote regression neovascularization tufts normal lesions. Modulating state microglial activation ameliorate thus appears as promising potential therapeutic approach managing Graphical abstract

Language: Английский

Citations

12
Evaluation of regulatory T-cells in cancer immunotherapy: therapeutic relevance of immune checkpoint inhibition DOI
Ranjeet Singh, Prateek Srivastava, Partha Pratim Manna

et al.

Medical Oncology, Journal Year: 2024, Volume and Issue: 41(2)

Published: Jan. 18, 2024

Language: Английский

Citations

6
The efficacy and safety of induction chemotherapy combined with sintilimab followed by concurrent chemoradiotherapy plus sintilimab sequencing maintaining with sintilimab for patients with unresectable locally advanced esophageal squamous cell carcinoma DOI Creative Commons
R. Wang,

Tianhui Guo,

Qi Wang

et al.

BMC Cancer, Journal Year: 2025, Volume and Issue: 25(1)

Published: Jan. 16, 2025

Language: Английский

Citations

0
A preoperative predictive model based on multi-modal features to predict pathological complete response after neoadjuvant chemoimmunotherapy in esophageal cancer patients DOI Creative Commons
Yana Qi, Yanran Hu, Lin Cai

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Jan. 27, 2025

Background This study aimed to develop a multi-modality model by incorporating pretreatment computed tomography (CT) radiomics and pathomics features along with clinical variables predict pathologic complete response (pCR) neoadjuvant chemoimmunotherapy in patients locally advanced esophageal cancer (EC). Method A total of 223 EC who underwent followed surgical intervention between August 2021 December 2023 were included this study. Radiomics extracted from contrast-enhanced CT images using PyrRadiomics, while derived whole-slide (WSIs) pathological specimens fine-tuned deep learning (ResNet-50). After feature selection, three single-modality prediction models combined integrating two features, 11 clinicopathological constructed the support vector machine (SVM) algorithm. The performance evaluated receiver operating characteristic (ROC) analysis, calibration plots, decision curve analysis (DCA). Shapley values also utilized explain model. Results predictive capability predicting pCR yielded an area under (AUC) 0.89 (95% confidence interval [CI], 0.75-1.00), outperforming (AUC 0.70 [95% CI 0.54-0.85]), 0.77 0.53-1.00]), 0.63 0.46-0.80]). Additionally, both plot DCA curves utility integrated Conclusions we propose can better status help inform treatment decisions.

Language: Английский

Citations

0
Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma DOI Creative Commons
Huilai Lv, Fan Zhang, Chao Huang

et al.

Journal of Cancer Research and Clinical Oncology, Journal Year: 2024, Volume and Issue: 150(5)

Published: May 17, 2024

Abstract Purpose Neoadjuvant chemotherapy (NCT) is the standard preoperative treatment for resectable locally advanced esophageal squamous cell carcinoma (ESCC). Some studies reported neoadjuvant immunochemotherapy (NICT) could improve pathological response with manageable safety. However, few have compared efficacy and safety of NICT NCT, especially survival outcomes. In this study, we NCT after a median follow-up 36.0 months. Methods This was retrospective study 1:1 propensity score matching (PSM). Locally ESCC patients treated sintilimab plus or followed by esophagectomy were reviewed. The primary outcome recurrence-free (RFS). Results Forty-five identified in each group PSM. complete (pCR) rate 28.9% 8.9% (P = 0.02). hazard ratio (HR) 0.396 (95% CI 0.171–0.919, p 0.025) RFS 0.377 0.145–0.981, 0.038) overall (OS), 3-year 80.6% 62.1%, OS 86.2% 68.1%. Patients pCR, MPR downstaging had better OS. incidences postoperative complications treatment-related adverse events (TRAEs) similar. Conclusion trial preliminarily shows that improves outcomes over ESCC, acceptable

Language: Английский

Citations

2
Efficacy, safety, and survival of neoadjuvant immunotherapy plus chemotherapy in locally advanced esophageal squamous cell carcinoma: A real-world retrospective study DOI Creative Commons
Yiyu Guo, Xinyu Xu,

Tian Wang

et al.

International Immunopharmacology, Journal Year: 2024, Volume and Issue: 138, P. 112558 - 112558

Published: June 27, 2024

This study aims to analyze the efficacy and safety of neoadjuvant programmed cell death-1 (PD-1) blockade plus chemotherapy in real-world applications. Additionally, we report survival outcomes with a median follow-up 40.1 months.

Language: Английский

Citations

2
Jin-Gui-Shen-Qi Wan ameliorates diabetic retinopathy by inhibiting apoptosis of retinal ganglion cells through the Akt/HIF-1α pathway DOI Creative Commons
Dan Liang,

Yulin Qi,

Lu Liu

et al.

Chinese Medicine, Journal Year: 2023, Volume and Issue: 18(1)

Published: Oct. 12, 2023

Jin-Gui-Shen-Qi Wan (JGSQ) has been used in China for thousands of years to treat various ailments, including frequent urination, blurred vision, and soreness the waist knees. It traditional therapeutic advantages improving eye diseases.Clinical studies have confirmed efficacy JGSQ diabetes vision; however, its pharmacological effects treating diabetic retinopathy (DR) remain unclear. Therefore, aim this study was investigate specific potential mechanisms DR through a db/db model.db/db mice were given three different doses orally administered metformin 8 weeks, then PAS staining retinal vascular network patch, transmission electron microscopy, H&E staining, TUNEL performed determine role DR-induced neuronal cell apoptosis. Furthermore, pharmacology analysis molecular docking carried out identify main targets JGSQ, evaluated western blotting immunofluorescence revealing mechanism action.According results from H&E, TUNEL, patch does not an advantage abnormal morphology endothelial cells, but it significant effect on protecting ganglion cells Through docking, AKT, GAPDH, TNF, TP53, IL-6 identified as core JGSQ. Subsequently, blot found that can inhibit HIF-1α, promote p-AKT expression, TP53 expression. At same time, inhibiting release inflammatory factors protects improves apoptosis DR.These indicated mouse model, expression cytokines protect apoptosis, possibly by modulating Akt/HIF-1α pathway.

Language: Английский

Citations

6
Study on the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy regimen for III–IVA esophageal squamous cell carcinoma post-surgery DOI Creative Commons
Chunyang Li,

Pengyi Yu,

Hong Li

et al.

Journal of Cardiothoracic Surgery, Journal Year: 2024, Volume and Issue: 19(1)

Published: Jan. 25, 2024

Abstract Background and aims The treatment of esophageal squamous cell carcinoma is still controversial, neoadjuvant chemotherapy combined with immunotherapy a hot topic current research. We investigated the recent efficacy surgical safety patients III–IVA after regimen paclitaxel + cisplatin/nedaplatin/carboplatin sindilizumab, to provide theoretical basis for evaluating feasibility surgery therapy. Methods clinical data stage admitted from January 2022 April 2023 at our hospital were collected retrospective analysis. divided into combination group (34 sintilimab two/three cycles preoperative therapy) surgery-only (36 patients). Statistical analysis was performed compare differences between both groups particularly intraoperative bleeding, operative time, incidence postoperative pulmonary complications, laryngeal recurrent nerve injury, thoracic duct anastomotic fistula, days. Additionally, pCR/MPR rates analysed. Results Significant present in pathological staging before ( P ≤ 0.001). had pCR rate 26.47% an ORR 88.23%. No significant discovered R0 resection groups, as well injury rate, anastomosis incidence, days, lung infection > 0.05). Conclusions immune considerable tumor regression remission benefits, without reducing surgery, possibly presenting new plan.

Language: Английский

Citations

2
Efficacy and Safety of Pembrolizumab Combined with Albumin-Bound Paclitaxel and Nedaplatin for Advanced Esophageal Squamous Cell Carcinoma DOI Creative Commons
Fang Yan, Longpei Chen,

Mingzhen Ying

et al.

Immunotherapy, Journal Year: 2024, Volume and Issue: 16(5), P. 305 - 317

Published: Jan. 10, 2024

Objective: This research aimed to assess the efficacy and safety of pembrolizumab (PBL) combined with albumin-bound paclitaxel (ab-Pac) nedaplatin (NDP) for advanced esophageal squamous cell carcinoma (ESCC). Methods: A total 47 ESCC patients were administered PBL or NDP on day 1 ab-Pac days 8, every 21 one cycle. Tumor toxicities evaluated two cycles cycle, respectively. Results: The objective response rate was 68.1% disease control 100%. median follow-up 16.7 months; progression-free overall survival 12.6 19.9 months, Conclusion: combination proved be an effective safe treatment regimen ESCC.

Language: Английский

Citations

1
The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma DOI Creative Commons
Zheng Zhao,

Ming-Mei Yin,

Weifeng Zhao

et al.

Medicine, Journal Year: 2023, Volume and Issue: 102(33), P. e34794 - e34794

Published: Aug. 18, 2023

Immunotherapy is a new treatment option for patients with esophageal squamous cell carcinoma (ESCC). However, no study has investigated the efficacy and safety of sintilimab combined nanoparticle albumin-bound paclitaxel (Nab-PTX) platinum as first-line metastatic ESCC. In this retrospective study, eligible ESCC were administered plus Nab-PTX, cisplatin, or nedaplatin up to 4 6 cycles. Subsequently, without progressive disease (PD) continued receive every 3 weeks maintenance until unacceptable toxicity, PD, withdrawal consent, 2 years. The primary endpoint was objective response rate (ORR) secondary endpoints progression-free survival (PFS), overall (OS), control (DCR), safety. A total 22 diagnosed enrolled, 1 patient reached complete (CR), 15 achieved partial (PR), had stable disease, PD. ORR 72.7% (16/22) DCR 90.9% (20/22). time 1.9 months (95% confidence interval [CI]:1.7-2.2 months). median PFS 8.9 CI, 7.1-10.7 months), OS 19.0 months. Exploratory biomarker analysis revealed that lactic dehydrogenase (LDH) potential marker OS, high LDH levels shorter mOS (13.0 months, 95% CI:7.5-18.5 Treatment-related adverse events (AEs) occurred in 21 (95.5%), most which grade 2. No treatment-related deaths study. results suggested Nab-PTX significantly encouraging mPFS mOS. profile manageable.

Language: Английский

Citations

2